Stay updated with breaking news from Emyria Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Therapeutic Goods Administration released an Independent Expert Panel Report reviewing the therapeutic potential of MDMA and psilocybin ahead of...
Join three emerging lifescience companies as they present their investment cases at Proactive's Lifesciences Webinar at 12pm AEST on Tuesday, September...
The data show that on average opioid consumption reduces after commencing care at Emerald Clinics from a previous 12 month steady-state of opioid use.
The Emyria Ltd (ASX: EMD) share price is climbing following a positive announcement to service its growing demand. We take a closer look.